IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
27 05 2021
27 05 2021
Historique:
received:
21
07
2020
accepted:
14
11
2020
pubmed:
20
11
2020
medline:
15
12
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
B-cell receptor (BCR) signaling is crucial for chronic lymphocytic leukemia (CLL) biology. IGLV3-21-expressing B cells may acquire a single point mutation (R110) that triggers autonomous BCR signaling, conferring aggressive behavior. Epigenetic studies have defined 3 CLL subtypes based on methylation signatures reminiscent of naïve-like (n-CLL), intermediate (i-CLL), and memory-like (m-CLL) B cells with different biological features. i-CLL carries a borderline IGHV mutational load and significantly higher use of IGHV3-21/IGLV3-21. To determine the clinical and biological features of IGLV3-21R110 CLL and its relationship to these epigenetic subtypes, we characterized the immunoglobulin gene of 584 CLL cases using whole-genome/exome and RNA sequencing. IGLV3-21R110 was detected in 6.5% of cases: 30 (38%) of 79 i-CLLs, 5 (1.7%) of 291 m-CLLs, and 1 (0.5%) of 189 n-CLLs. All stereotype subset 2 cases carried IGLV3-21R110, whereas 62% of IGLV3-21R110 i-CLL cases had nonstereotyped BCR immunoglobulins. IGLV3-21R110 i-CLL had a significantly higher number of SF3B1 and ATM mutations and total number of driver alterations. However, the R110 mutation was the sole alteration in 1 i-CLL and was accompanied only by del(13q) in 3. Although IGHV mutational status varied, IGLV3-21R110 i-CLL transcriptomically resembled n-CLL/unmutated IGHV CLL with a specific signature including WNT5A/B overexpression. In contrast, i-CLL lacking IGLV3-21R110 mirrored m-CLL/mutated IGHV. Patients with IGLV3-21R110 i-CLL had a short time to first treatment and overall survival similar to those of n-CLL/unmutated IGHV patients, whereas patients with non-IGLV3-21R110 i-CLL had a good prognosis similar to that of patients with m-CLL/mutated IGHV. IGLV3-21R110 defines a CLL subgroup with specific biological features and an unfavorable prognosis independent of IGHV mutational status and epigenetic subtype.
Identifiants
pubmed: 33211804
pii: S0006-4971(21)01092-2
doi: 10.1182/blood.2020008311
pmc: PMC8191863
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2935-2946Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 by The American Society of Hematology.
Références
J Exp Med. 2012 Nov 19;209(12):2183-98
pubmed: 23091163
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Genet. 2016 Mar;48(3):253-64
pubmed: 26780610
Nat Commun. 2020 Jul 7;11(1):3390
pubmed: 32636395
Nucleic Acids Res. 2009 Jan;37(Database issue):D1006-12
pubmed: 18978023
Nature. 2012 Sep 13;489(7415):309-12
pubmed: 22885698
J Exp Med. 2001 Dec 3;194(11):1625-38
pubmed: 11733577
Blood. 2011 Jan 13;117(2):563-74
pubmed: 20940416
Blood. 2006 Apr 1;107(7):2889-94
pubmed: 16317103
Clin Cancer Res. 2018 Oct 15;24(20):5048-5057
pubmed: 29945996
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Blood. 2019 Aug 22;134(8):688-698
pubmed: 31292113
Blood. 2007 Apr 1;109(7):2989-98
pubmed: 17148579
J Clin Invest. 2016 Feb;126(2):585-98
pubmed: 26690702
Bioinformatics. 2012 Dec 15;28(24):3211-7
pubmed: 23071270
J Clin Invest. 2018 Jan 2;128(1):427-445
pubmed: 29227286
Nat Genet. 2012 Nov;44(11):1236-42
pubmed: 23064414
Clin Cancer Res. 2016 Jan 15;22(2):459-69
pubmed: 26240275
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Rev Dis Primers. 2017 Jan 19;3:16096
pubmed: 28102226
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Leukemia. 2017 Feb;31(2):282-291
pubmed: 27811850
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Leukemia. 2005 Nov;19(11):2002-5
pubmed: 16121219
Bioinformatics. 2019 Jun 1;35(12):2084-2092
pubmed: 30395178
Nat Commun. 2017 Jun 09;8:15746
pubmed: 28598442
Blood. 2012 May 10;119(19):4467-75
pubmed: 22415752
Leukemia. 2015 Mar;29(3):598-605
pubmed: 25151957
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Blood. 2002 Mar 15;99(6):2262-4
pubmed: 11877310
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8
pubmed: 18503082
Blood. 2003 Jun 15;101(12):4944-51
pubmed: 12595313
Annu Rev Pathol. 2020 Jan 24;15:149-177
pubmed: 31977296
Nature. 2019 Oct;574(7780):712-716
pubmed: 31597163
Nature. 2015 Oct 22;526(7574):525-30
pubmed: 26466571
J Clin Oncol. 2004 Oct 1;22(19):3937-49
pubmed: 15459216
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Bioinformatics. 2015 Dec 1;31(23):3844-6
pubmed: 26249808
Leukemia. 2006 Oct;20(10):1774-82
pubmed: 16932341
J Exp Med. 2001 Dec 3;194(11):1639-47
pubmed: 11733578
Blood Adv. 2019 Aug 27;3(16):2474-2481
pubmed: 31434681
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4320-4327
pubmed: 32047037
Blood. 2005 Jul 15;106(2):681-9
pubmed: 15817677
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Blood. 2007 Jan 1;109(1):259-70
pubmed: 16985177
Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713